Ozempic vs Wegovy: What Is the Difference Between These Injections?
When comparing Ozempic vs. Wegovy, the most important fact is that both contain semaglutide, and both now come as a weekly injection or a daily pill. Their main differences are their approved uses, dosing schedules, and insurance coverage. Ozempic treats adults with type 2 diabetes, while Wegovy supports long-term weight management in eligible adults. Wegovy injection is also approved for adolescents aged 12 and older with obesity; the tablets are approved only for adults.
Shop Medications
Although these products share an active ingredient, their doses and approved benefits are not identical. The right choice depends on your diagnosis, treatment goals, and whether you prefer a weekly injection or a daily tablet with fasting requirements. This guide explains how oral and injectable Ozempic and Wegovy compare for dosing, weight loss, heart health, side effects, and affordability.
In This Article
- What Is the Main Difference Between Ozempic and Wegovy?
- How Do the Ozempic vs Wegovy Dosage Schedules Compare?
- Which Medication Works Better for Weight Loss?
- How Do Ozempic and Wegovy Protect Heart Health?
- What Are the Common Side Effects of Ozempic and Wegovy?
- What Are the Serious but Rare Side Effects?
- How Do Insurance Coverage and Costs Differ for Ozempic vs Wegovy?
- Can Your Doctor Switch You Between Ozempic and Wegovy?
- Which Medication Is Right for You?
- References
What Is the Main Difference Between Ozempic and Wegovy?
The main difference between Ozempic and Wegovy is their approved purpose—not simply whether they come as a shot or pill. Both brands offer oral and injectable semaglutide, but Ozempic is approved for type 2 diabetes rather than specifically for weight management.
Wegovy tablets are approved for weight management in adults with obesity, or overweight with a weight-related condition. Wegovy injection also has an adolescent obesity indication and an accelerated approval for certain adults with metabolic dysfunction-associated steatohepatitis, or MASH, with moderate-to-advanced liver scarring.

Why Pay Full Price?
Search our full medication catalogue and save up to 80% - no insurance needed.
See Prices NowSemaglutide belongs to the GLP-1 receptor agonist family. It helps regulate insulin release, slows stomach emptying, and affects appetite. Rybelsus is another oral semaglutide product for diabetes, but its tablet strengths differ from oral Ozempic.
How Do the Ozempic vs Wegovy Dosage Schedules Compare?
Dosing depends on both the brand and formulation. Tablet strengths cannot be directly compared with injection strengths because the body absorbs them differently.
| Product | Starting dose | Dose progression |
|---|---|---|
| Ozempic injection | 0.25 mg weekly for 4 weeks | Increase to 0.5 mg; further increases to 1 or 2 mg depend on treatment needs |
| Ozempic tablets | 1.5 mg daily for 30 days | Increase to 4 mg; may increase to 9 mg from day 61 |
| Wegovy injection | 0.25 mg weekly for 4 weeks | Increase through 0.5, 1, and 1.7 mg; usual recommended maintenance is 2.4 mg |
| Wegovy tablets | 1.5 mg daily for 30 days | Increase every 30 days to 4, 9, then 25 mg daily |
Wegovy HD, a 7.2 mg weekly injection, is another option for certain adults needing additional weight reduction. It is not a starting dose. Patients must first tolerate 2.4 mg for at least four weeks before a prescriber considers increasing it.
Both oral products require an empty stomach in the morning, no more than 4 ounces of plain water, and a wait of at least 30 minutes before food, other drinks, or oral medications. Swallow tablets whole. Weekly injections do not require fasting.
Injection devices vary by presentation, so follow the instructions for your specific product.
Which Medication Works Better for Weight Loss?
Wegovy is specifically approved for weight management, while Ozempic’s doses and studies primarily address diabetes. However, results depend on the formulation, dose, study population, and ability to continue treatment.
In STEP 1, adults without diabetes receiving injectable semaglutide 2.4 mg lost an average of 14.9% of their starting weight over 68 weeks, compared with 2.4% with placebo.
Oral Wegovy also has weight-loss evidence. In OASIS 4, adults without diabetes receiving oral semaglutide 25 mg lost an estimated 13.6% over 64 weeks, versus 2.2% with placebo, regardless of treatment discontinuation.
These were separate trials—not a direct pill-versus-injection comparison. The percentages do not prove that one formulation works better than another. Both studies included lifestyle support.
How Do Ozempic and Wegovy Protect Heart Health?
The approved cardiovascular benefits differ by product and patient group.
Ozempic injection reduces major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Oral Ozempic has this indication for adults with type 2 diabetes who are at high risk for these events, including people without previously diagnosed cardiovascular disease.
Both oral and injectable Wegovy are approved to reduce major cardiovascular events in adults with established cardiovascular disease and overweight or obesity.
The SELECT trial tested injectable semaglutide 2.4 mg in adults with cardiovascular disease and excess weight but no diabetes. Major cardiovascular events occurred in 6.5% receiving semaglutide versus 8.0% receiving placebo—a 20% relative reduction. This result should not be presented as a separate cardiovascular-outcomes trial of Wegovy tablets.
Ozempic injection also has a kidney-protection indication for adults with type 2 diabetes and chronic kidney disease.
What Are the Common Side Effects of Ozempic and Wegovy?
Oral and injectable semaglutide can cause nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Symptoms commonly occur when treatment starts or the dose increases, although they do not resolve for everyone.
Taking a pill does not eliminate digestive side effects. Likewise, a higher milligram number on an oral product does not automatically mean more side effects than a lower-dose injection.
Smaller meals, slower eating, and avoiding foods that worsen symptoms may help. Drink fluids regularly, particularly during vomiting or diarrhea.
Contact your healthcare provider if symptoms persist, become severe, or prevent adequate fluid intake. Side-effect percentages from different trials should not be treated as direct comparisons between products.
What Are the Serious but Rare Side Effects?
Potentially serious risks include pancreatitis, gallbladder disease, severe allergic reactions, kidney injury associated with dehydration, and severe digestive problems. These risks do not all occur at the same frequency, so a single “less than 1%–2%” estimate would be misleading.
Semaglutide is not recommended for people with severe gastroparesis. People with diabetic retinopathy may need monitoring, and low blood sugar becomes more likely when treatment is combined with insulin or a sulfonylurea.
All forms carry a boxed warning about thyroid C-cell tumors observed in rodents. The human risk is unknown. They must not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Seek emergency care for breathing difficulty or swelling of the face, tongue, or throat. Tell your healthcare team about planned procedures because delayed stomach emptying can affect anesthesia safety.
How Do Insurance Coverage and Costs Differ for Ozempic vs Wegovy?
Check coverage for the exact product: Ozempic injection, Ozempic tablets, Wegovy injection, or Wegovy tablets. Coverage for one does not guarantee coverage for another.
Your diagnosis, plan exclusions, prior authorization requirements, deductible, and pharmacy network can all affect what you pay. An approved indication does not automatically mean your insurer will cover treatment.
Ask your insurer about covered alternatives and manufacturer assistance eligibility before switching.
If comparing options through Universal Drugstore, check the exact strength, formulation, quantity, country of supply, and total price. Brand names and presentations can differ internationally. Review current pricing and prescription requirements, and confirm any proposed substitution with your pharmacist or prescriber rather than assuming it matches the U.S. product.
Can Your Doctor Switch You Between Ozempic and Wegovy?
Yes, but switching requires product-specific instructions. There is no universal conversion that applies to every semaglutide pill and injection.
For example, Wegovy labeling provides a transition from the 2.4 mg weekly injection to the 25 mg daily tablet one week after the final injection. That does not mean oral Ozempic 9 mg is interchangeable with oral Wegovy 25 mg.
Your prescriber should consider your current dose, treatment interruption, side effects, diagnosis, and blood sugar before choosing the replacement and starting date. Do not combine oral and injectable semaglutide products.
Do not stop or change medications without talking to your healthcare provider first.
Which Medication Is Right for You?
The best choice depends on your diagnosis, approved treatment options, medical history, daily routine, and coverage.
For type 2 diabetes, Ozempic offers both daily tablets and weekly injections. For eligible adults seeking weight management, Wegovy also offers both routes. Adolescent treatment requires a different discussion because oral Wegovy is not approved for that age group.
A pill may appeal if you dislike needles and can follow the fasting instructions consistently. A weekly injection may fit better if mornings are unpredictable.
Discuss the specific product—not just the brand name—with your healthcare provider. The goal is a treatment you can use safely, tolerate, afford, and continue.
References
- Ozempic injection: prescribing information. Novo Nordisk. Revised May 2026. Accessed November 9, 2026.
- Rybelsus and Ozempic tablets: prescribing information. Novo Nordisk. Revised January 2026. Accessed November 9, 2026.
- Wegovy injection and tablets: prescribing information. Novo Nordisk. Accessed November 9, 2026.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183. Accessed November 9, 2026.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. Accessed November 9, 2026.
- Wharton S, et al. OASIS 4 Study Group. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025 Sep 18;393(11):1077-1087. Accessed November 9, 2026.
- Cleto AS, et al. Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis. Int J Obes (Lond). 2025 Jan;49(1):21-30. Accessed November 9, 2026.